From: Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
Controls | MCI-AD | ADD | |
---|---|---|---|
N (male + female) | 41 (22 + 19) | 25 (10 + 15) | 33 (13 + 20) |
Age (years) | 52.5 ± 13.1 | 71.3 ± 8.4 | 70.8 ± 7.6 |
MMSE | 29.3 ± 0.9a | 26.7 ± 2.1b | 21.2 ± 3.4 |
CSF Aβ1–42 (pg/mL) | 1025 ± 308 | 585 ± 116 | 536 ± 114 |
CSF Aβ1–40 (pg/mL) | 13,598 ± 4046 | 19,171 ± 5689 | 15,309 ± 4172 |
CSF Aβ42/40 | 0.076 ± 0.01 | 0.032 ± 0.01 | 0.036 ± 0.006 |
CSF Tau (pg/mL) | 198 ± 64.4 | 631 ± 214 | 558 ± 178 |
CSF pTau181 (pg/mL) | 37.3 ± 12.1 | 101.4 ± 29.8 | 89.9 ± 18.4 |
Plasma NfL (pg/mL) | 22.0 ± 12.4 | 38.1 ± 15.9 | 49.1 ± 28.4 |